Rutaecarpine induces the differentiation of triple-negative breast cancer cells through inhibiting fumarate hydratase.
3D morphological screening
Differentiation therapy
Rutaecarpine
Journal
Journal of translational medicine
ISSN: 1479-5876
Titre abrégé: J Transl Med
Pays: England
ID NLM: 101190741
Informations de publication
Date de publication:
18 08 2023
18 08 2023
Historique:
received:
10
05
2023
accepted:
29
07
2023
medline:
21
8
2023
pubmed:
18
8
2023
entrez:
17
8
2023
Statut:
epublish
Résumé
Triple-negative breast cancer (TNBC) is one of the most aggressive human cancers and has poor prognosis. Approximately 80% of TNBC cases belong to the molecular basal-like subtype, which can be exploited therapeutically by inducing differentiation. However, the strategies for inducing the differentiation of TNBC remain underexplored. A three-dimensional (3D) morphological screening model based on a natural compound library was used to identify possible candidate compounds that can induce TNBC cell differentiation. The efficacy of rutaecarpine was verified using assays: RT-qPCR, RNA-seq, flow cytometry, immunofluorescence, SCENITH and label-free LC-MS/MS. The direct targets of rutaecarpine were identified through drug affinity responsive target stability (DARTS) assay. A xenograft mice model was also constructed to confirm the effect of rutaecarpine in vivo. We identified that rutaecarpine, an indolopyridoquinazolinone, induces luminal differentiation of basal TNBC cells in both 3D spheroids and in vivo mice models. Mechanistically, rutaecarpine treatment leads to global metabolic stress and elevated ROS in 3D cultured TNBC cells. Moreover, NAC, a scavenger of ROS, impedes rutaecarpine-induced differentiation of TNBC cells in 3D culture. Finally, we identified fumarate hydratase (FH) as the direct interacting target of rutaecarpine. The inhibition of FH and the knockdown of FH consistently induced the differentiation of TNBC cells in 3D culture. Our results provide a platform for differentiation therapy drug discovery using 3D culture models and identify rutaecarpine as a potential compound for TNBC treatment.
Sections du résumé
BACKGROUND
Triple-negative breast cancer (TNBC) is one of the most aggressive human cancers and has poor prognosis. Approximately 80% of TNBC cases belong to the molecular basal-like subtype, which can be exploited therapeutically by inducing differentiation. However, the strategies for inducing the differentiation of TNBC remain underexplored.
METHODS
A three-dimensional (3D) morphological screening model based on a natural compound library was used to identify possible candidate compounds that can induce TNBC cell differentiation. The efficacy of rutaecarpine was verified using assays: RT-qPCR, RNA-seq, flow cytometry, immunofluorescence, SCENITH and label-free LC-MS/MS. The direct targets of rutaecarpine were identified through drug affinity responsive target stability (DARTS) assay. A xenograft mice model was also constructed to confirm the effect of rutaecarpine in vivo.
RESULTS
We identified that rutaecarpine, an indolopyridoquinazolinone, induces luminal differentiation of basal TNBC cells in both 3D spheroids and in vivo mice models. Mechanistically, rutaecarpine treatment leads to global metabolic stress and elevated ROS in 3D cultured TNBC cells. Moreover, NAC, a scavenger of ROS, impedes rutaecarpine-induced differentiation of TNBC cells in 3D culture. Finally, we identified fumarate hydratase (FH) as the direct interacting target of rutaecarpine. The inhibition of FH and the knockdown of FH consistently induced the differentiation of TNBC cells in 3D culture.
CONCLUSIONS
Our results provide a platform for differentiation therapy drug discovery using 3D culture models and identify rutaecarpine as a potential compound for TNBC treatment.
Identifiants
pubmed: 37592347
doi: 10.1186/s12967-023-04396-w
pii: 10.1186/s12967-023-04396-w
pmc: PMC10436383
doi:
Substances chimiques
rutecarpine
8XZV289PRY
Fumarate Hydratase
EC 4.2.1.2
Reactive Oxygen Species
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
553Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
N Engl J Med. 2018 Nov 29;379(22):2108-2121
pubmed: 30345906
Cell Death Dis. 2023 Jun 23;14(6):370
pubmed: 37353480
J Hematol Oncol. 2022 Oct 18;15(1):148
pubmed: 36258250
Nat Rev Cancer. 2014 Nov;14(11):709-21
pubmed: 25342630
Breast Cancer Res. 2020 Jun 9;22(1):61
pubmed: 32517735
Cell Signal. 2023 Jan;101:110525
pubmed: 36400383
Biomed Pharmacother. 2018 Feb;98:82-87
pubmed: 29245070
Nature. 2016 Apr 14;532(7598):255-8
pubmed: 27049945
Cancer Discov. 2022 Jan;12(1):31-46
pubmed: 35022204
Nat Cell Biol. 2013 Feb;15(2):201-13
pubmed: 23354167
Biochim Biophys Acta. 2013 Dec;1833(12):3481-3498
pubmed: 23830918
Nat Rev Dis Primers. 2019 Sep 23;5(1):66
pubmed: 31548545
Nature. 2014 Jun 19;510(7505):397-401
pubmed: 24828042
Chin J Cancer. 2016 Jan 06;35:3
pubmed: 26739838
Mol Cell. 2020 Jan 16;77(2):213-227.e5
pubmed: 31735641
Cancer Cell Int. 2023 Feb 20;23(1):29
pubmed: 36803831
J Nat Prod. 2022 May 27;85(5):1407-1418
pubmed: 35544614
Nat Commun. 2017 Jul 5;8(1):59
pubmed: 28680106
J Nat Prod. 2020 Mar 27;83(3):770-803
pubmed: 32162523
Mol Ther Nucleic Acids. 2019 Sep 6;17:24-37
pubmed: 31195298
Nat Rev Clin Oncol. 2022 Feb;19(2):91-113
pubmed: 34754128
Nat Commun. 2013;4:2550
pubmed: 24096541
Semin Cell Dev Biol. 2020 Feb;98:15-25
pubmed: 31085323
Curr Opin Cell Biol. 2017 Dec;49:1-8
pubmed: 29175320
Nature. 2020 Apr;580(7801):136-141
pubmed: 32238925
J Hematol Oncol. 2021 Mar 23;14(1):49
pubmed: 33757574
Pharmacol Res. 2019 Mar;141:541-550
pubmed: 30616017
Cell Stem Cell. 2021 Feb 4;28(2):300-314.e6
pubmed: 33275875
Trends Cell Biol. 2011 Dec;21(12):745-54
pubmed: 22033488
Oncotarget. 2016 Jul 19;7(29):46419-46432
pubmed: 27329840
Theranostics. 2022 Jan 1;12(2):720-733
pubmed: 34976209
Development. 2014 Nov;141(22):4206-18
pubmed: 25371358
Mol Cancer. 2017 Apr 13;16(1):79
pubmed: 28407774
J Transl Med. 2014 Jul 31;12:200
pubmed: 25082261
Nat Rev Clin Oncol. 2018 Jun;15(6):347-348
pubmed: 29555966
Free Radic Biol Med. 2020 Feb 20;148:33-41
pubmed: 31874248
Cancer Epidemiol Biomarkers Prev. 2017 Apr;26(4):444-457
pubmed: 28223433
Blood. 2021 May 6;137(18):2429-2437
pubmed: 33651885
Cell Metab. 2019 Aug 6;30(2):274-289.e5
pubmed: 31056285
Cell Metab. 2020 Dec 1;32(6):1063-1075.e7
pubmed: 33264598
Cell Stem Cell. 2016 Aug 4;19(2):232-247
pubmed: 27237737
Cancer Discov. 2018 Aug;8(8):935-943
pubmed: 29899062
Lancet. 2021 May 8;397(10286):1750-1769
pubmed: 33812473
Nature. 2023 Mar;615(7952):499-506
pubmed: 36890229
Cancer Treat Rev. 2020 Aug;88:102060
pubmed: 32619863
Trends Biotechnol. 2013 Feb;31(2):108-15
pubmed: 23336996
Cell. 2015 Oct 22;163(3):560-9
pubmed: 26496603
Nature. 2009 Sep 3;461(7260):109-13
pubmed: 19693011
Ann Oncol. 2012 Aug;23 Suppl 6:vi19-22
pubmed: 23012297
Nat Commun. 2016 Jan 19;7:10180
pubmed: 26782714
Ann Transl Med. 2020 Oct;8(20):1295
pubmed: 33209875
Cell Rep. 2017 Jan 10;18(2):468-481
pubmed: 28076790
Mol Cell. 2013 Jul 25;51(2):236-48
pubmed: 23747014
Cancers (Basel). 2022 May 19;14(10):
pubmed: 35626094
Nat Commun. 2021 Jul 12;12(1):4262
pubmed: 34253738
Cell Metab. 2018 Jul 03;28(1):69-86.e6
pubmed: 29972798
Cell Signal. 2023 Jan;101:110504
pubmed: 36309329
Nat Rev Cancer. 2018 Feb;18(2):117-127
pubmed: 29192213
Science. 2016 Mar 4;351(6277):aad3680
pubmed: 26941323
Cell Metab. 2015 May 5;21(5):777-89
pubmed: 25955212
Cell Stem Cell. 2017 Nov 2;21(5):679-693.e6
pubmed: 29033351
J Am Chem Soc. 2015 Jan 21;137(2):564-7
pubmed: 25469852